ImaginAb, Inc., a market leading global biotechnology company focused on developing next generation ImmunoPET imaging agents and therapeutic radiopharmaceuticals (RPT), is pleased to announce it has signed a new multi-year, non-exclusive supply agreement with Genmab A/S, an international biotechnology company.
Under the terms of the agreement, ImaginAb will provide a non-exclusive, worldwide license to Genmab A/S to use its investigational CD8 ImmunoPET imaging technology (zirconium Zr 89 crefmirlimab berdoxam) in clinical trials.
Commenting on the announcement, Ian Wilson, Chief Executive Officer of ImaginAb stated:
“We are delighted to announce this new supply agreement with Genmab A/S, who, under the agreement, will utilize our CD8 ImmunoPET agent, global supply chain, and validated Clinical PET sites in their future clinical trials.
“We are continuing to invest in the clinical development and global supply chain to provide access to this clinical stage investigational imaging agent. CD8 T cells play a pivotal role in immunotherapy and the use of our agent is becoming an established method used by pharmaceutical and biotech companies to visualize and track CD8 cells in clinical trial subjects. Our ultimate goal is to gain regulatory approval for the agent in multiple geographies, allowing the use and adoption of the agent in the management of cancer patients.”